The Neutrophil to Lymphocyte Ratio as a Prognostic Indicator in Patients with Breast Cancer: A Retrospective Study at Seyed Al-Shohada Hospital, Isfahan

Document Type : Original Article (s)

Authors

1 Associate, Department of Internal Medicine, School of Medicine, Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant, Department of Biomaterials, Nanotechnology and Tissue Engineering, School of Advanced Medical Technology, Biosensor Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate, Department of Epidemiology and Biostatistics, School of Health, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v43.i824.0846

Abstract

Background: Considering the high prevalence of breast cancer, the importance of determining the prognosis in planning the treatment of patients, the confirmed role of inflammation in the occurrence of cancers despite different results in previous studies and the lack of sufficient investigation, a study aimed to determine the value of the neutrophil-to-lymphocyte ratio in the prognosis of patients with breast cancer referred to Seyed al-Shohada Hospital in Isfahan.
Methods: This retrospective cross-sectional study was conducted on 219 breast cancer patients referred to Seyed al-Shohada Hospital from April 2016 to April 2020. The data available in the patients' files, such as the ratio of initial hemogram indicators, demographic indicators, disease stage at diagnosis, pathological criteria, and mortality rate of patients with breast cancer, were used. Data were analyzed using Student's t-test, Chi-square, analysis of variance, and the Kaplan-Meier method.
Findings: The findings of the study showed a statistically significant relationship between survival time and the neutrophil-to-lymphocyte ratio (NLR) (P < 0.01), where increased NLR was associated with decreased survival time. Also, the relationship between the disease stage and and the patients' NLR was significant, and the average NLR was higher in higher stages.
Conclusion: The neutrophil-to-lymphocyte ratio can be used as a useful prognostic marker in patients with breast cancer. The findings of the study can be used for related professionals and in the field of health.

Highlights

Mehran Sharifi Isfahani: Google Scholar

Laleh Shariati: Google Scholar

Maryam Nasirian : Google Scholar

Keywords

Main Subjects

References

  1. Amori N, Aghajani M, Asgarian FS, Jazayeri M. Epidemiology and trend of common cancers in Iran (2004-2008). Eur J Cancer Care (Engl) 2017; 26(5).
  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87-108.
  3. Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol 2022; 95(1130): 20211033.
  4. Thomas A, Rhoads A, Pinkerton E, Schroeder MC, Conway KM, Hundley WG, et al. Incidence and Survival Among Young Women With Stage I-III Breast Cancer: SEER 2000-2015. JNCI Cancer Spectr 2019; 3(3): pkz040.
  5. Taghavi A, Fazeli Z, Vahedi M, Baghestani AR, Pourhoseingholi A, Barzegar F, et al. Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev 2012; 13(1): 367-70.
  6. Martincich L, Deantoni V, Bertotto I, Redana S, Kubatzki F, Sarotto I, et al. Correlations between diffusion-weighted imaging and breast cancer biomarkers. Eur Radiol 2012; 22(7): 1519-28.
  7. Tyagi NK, Dhesy-Thind S. Clinical practice guidelines in breast cancer. Curr Oncol 2018; 25(Suppl 1): S151-S60.
  8. Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014; 32(13): 1365-83.
  9. Hadad SM, Jordan LB, Roy PG, Purdie CA, Iwamoto T, Pusztai L, et al. A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer. BMC Cancer 2016; 16(1): 745.
  10. Engstrøm MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat 2013; 140(3): 463-73.
  11. Fernandes JV, Cobucci RN, Jatobá CA, Fernandes TA, de Azevedo JW, de Araújo JM. The role of the mediators of inflammation in cancer development. Pathol Oncol Res 2015; 21(3): 527-34.
  12. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30(7): 1073-81.
  13. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454(7203): 436-44.
  14. Deshmukh SK, Srivastava SK, Poosarla T, Dyess DL, Holliday NP, Singh AP, et al. Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy. Ann Transl Med 2019; 7(20): 593.
  15. Aziz K, Nowsheen S, Pantelias G, Iliakis G, Gorgoulis VG, Georgakilas AG. Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy. Pharmacol Ther 2012; 133(3): 334-50.
  16. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity 2019; 51(1): 27-41.
  17. Sadri Nahand J, Moghoofei M, Salmaninejad A, Bahmanpour Z, Karimzadeh M, Nasiri M, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. Int J Cancer 2020; 146(2): 305-20.
  18. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010; 29(3): 405-34.
  19. Swierczak A, Mouchemore KA, Hamilton JA, Anderson RL. Neutrophils: important contributors to tumor progression and metastasis. Cancer Metastasis Rev 2015; 34(4): 735-51.
  20. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer 2016; 16(7): 431-46.
  21. Ou Q, Cheng J, Zhang L, Wang H, Wang W, Ma Y. The prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer: Deleterious or advantageous? T Tumour Biol 2017; 39(6): 1010428317706214.
  22. Ravelli A, Roviello G, Cretella D, Cavazzoni A, Biondi A, Cappelletti MR, et al. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. Tumour Biol 2017; 39(4): 1010428317695023.
  23. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28(1): 105-13.
  24. Cortazar P, Geyer CE, Jr. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol 2015; 22(5): 1441-6.
  25. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88(1): 218-30.
  26. Elyasinia F, Keramati MR, Ahmadi F, Rezaei S, Ashouri M, Parsaei R, et al. Neutrophil-Lymphocyte Ratio in Different Stages of Breast Cancer. Acta Med Iran 2017; 55(4): 228-32.
  27. Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 2017; 19(1): 2.
  28. Faria SS, Fernandes PC, Jr., Silva MJ, Lima VC, Fontes W, Freitas-Junior R, et al. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience 2016; 10: 702.
  29. Corbeau I, Jacot W, Guiu S. Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review. Cancers (Basel) 2020; 12(4): 958.
  30. Liu X, Qu JK, Zhang J, Yan Y, Zhao XX, Wang JZ, et al. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis. Medicine (Baltimore) 2017; 96(45): e8101.
Journal of Isfahan Medical School
Volume 43, Issue 824
4th Week, September
September and October 2025
Pages 846-852

Files

History

  • Receive Date: 14 June 2025
  • Accept Date: 19 July 2025

Share

How to cite

Statistics